Biomarker
Biomarkers: What is new?
August 14 by Joyce El HokayemHuman genetic research scientist, Dr Joyce El Hokayem, provides a concise overview of the emergence and future for biomarkers.
The Ascent of Precision Medicines
May 17 by Pharmaceuticals & Biotechnology EditorTraditionally the pharma industry has lent towards the view of a one-size fits all approach to the application of therapeutics. Now, eyes are set firmly on the notion of personalised medicine – therap...
Increasing Efficiency in Drug Discovery & Development with Aptuit Medicines Research Centre
September 07 by Andrea CharlesIn this podcast Mark Hembarsky, Vice President and Site Leader of the Aptuit Medicines Research Centre in Verona, Italy, and his colleagues Mauro Corsi, Head of Assay Development and In Vitro Profilin...
Troubleshooting Biomarker Development Strategies
June 09 by Gabriele DallmannIn this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical developme...
Update on Regulations Surrounding CNS in Europe: BfArM session on Optimising Clinical Development for CNS
January 11 by Pharma IQ NewsDr. Karl Broich, Vice President, BfArM, will discuss the new regulatory landscape as well as projected amendments to the current guidance documents on CNS clinical trials at Optimising Clinical...
Challenges and Opportunities in the Use of Biomarkers in Early Phase Trials
October 07 by Pharma IQIn this interview Martin Jenkins, Senior Statistician at AstraZeneca, speaks to Andrea Charles from Pharma IQ, about exploring the potential uses of biomarkers to enhance early clinical development,...
Improving Biomarker Development Work Flow in Phase I Clinical Development
September 07 by Helen WinsorReto Ossola, Group Leader for Biomarker Research at Biognosys, joins Pharma IQ to discuss the main challenges in biomarker development and some key ways to address these. Ossola offers some best...
Streamlining the Development and Validation Process in Discovery to Phase I Clinical Development
September 05 by Pharma IQReto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker de...
An Architecture-based Framework for Biomarker Discovery and Management in the Early Detection and Research
March 17 by Pharma IQPharma IQ speaks with Chris Mattmann, Ph.D., Senior Computer Scientist, NASA Jet Propulsion Laboratory, about an architecture-based framework for biomarker discovery and management in the early dete...